Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07129252 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Study acronym: BRAVESST2
StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 4 of 10 entries
    • Site details revised at 27 of 27 sites
  2. Study sites: 26 to 27v10
  3. Study sites: 24 to 26v9
  4. Trial sites expanded: 21 → 24 locationsv8
  5. Study sites: 19 to 21v7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 17 to 19v6
  2. Study sites: 15 to 17v5
  3. Study sites: 6 to 15v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 6
    • Start date changed from estimate of Oct 2025 to Nov 26, 2025
    v3
  5. Start date: Aug 2025 to Oct 2025v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This Phase 1/2, multicenter, open-label, FIH study aims to evaluate the safety, tolerability, PK, and preliminary antitumor activity of CRN09682 in participants with SST2-expressing NENs and other solid tumors. The study includes a Dose Escalation Phase to determine the MTD and DLTs. Following MTD identification, additional participants will be enrolled at the expansion dose to further assess safety, tolerability, PK, and antitumor activity.
Trial Details
NCT Number NCT07129252
Lead Sponsor Crinetics Pharmaceuticals Inc.
Conditions
(from sponsor)		 SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
Related terms Carcinoma, Neuroendocrine, Neoplasm Metastasis, Neuroendocrine Tumors
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov